{
    "symbol": "CHRS",
    "quarter": 4,
    "year": 2022,
    "date": "2023-03-06 22:22:04",
    "content": "  These statements include but are not limited to our ability to gain approval for multiple new products and launch them, the ability of the FDA to complete required inspections in China for our BLA for Toripalimab, timing of the end of our decline in revenues and timing of our ability to gain market share for any of our approved products, expectations about revenue growth, projections of expenses and revenue, our future manufacturing capacity, and whether we can return to profitability and the timing of any return to profitability."
}